An Indian generic-drug maker is seeking a comprehensive review by the Federal Court on the issue of “double patenting.” This action follows a recent panel decision that the company argues has inadvertently revived certain pharmaceutical patents, specifically those concerning an anti-diarrhea drug. The firm contends that the ruling is flawed and could have broader implications for the pharmaceutical industry. Read more.